Skip to main navigation Skip to search Skip to main content

An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

  • Andrzej P. Kudelka
  • , Rodger Winn
  • , Creighton L. Edwards
  • , G. Downey
  • , Harvey Greenberg
  • , S. R. Dakhil
  • , Ralph S. Freedman
  • , Salvatore LoCoco
  • , J. Umbreit
  • , James E. Delmore
  • , Susan Arbuck
  • , Evelyne Loyer
  • , Patsy Gacrama
  • , Rebecca Fueger
  • , John J. Kavanagh

    Research output: Contribution to journal › Article › peer-review

    Abstract

    Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

    Original languageEnglish (US)
    Pages (from-to)657-661
    Number of pages5
    JournalAnti-cancer drugs
    Volume8
    Issue number7
    DOIs
    StatePublished - 1997

    Keywords

    • Cervix cancer
    • Granulocyte colony stimulating factor
    • Paclitaxel

    ASJC Scopus subject areas

    • Oncology
    • Pharmacology
    • Pharmacology (medical)
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix'. Together they form a unique fingerprint.

    Cite this